Blood Test Flags Mantle Cell Lymphoma Relapse Before PET-CT
A recent study suggests that a blood test may be more effective than PET-CT scans in predicting relapses in patients with mantle cell lymphoma after CAR T-cell therapy. The blood test identified relapses a median of 6.5 months earlier than PET-CT scans in a small cohort of patients. Researchers advocate for the blood test's use in detecting minimal residual disease, although they caution that further studies are needed to validate its routine application over PET-CT scans.
- ▪The study involved 37 patients treated with brexucabtagene autoleucel at Stanford University.
- ▪In 15 of 18 patients who relapsed, the blood test identified relapse a median of 6.5 months before PET-CT scans.
- ▪Patients with detectable minimal residual disease had significantly worse progression-free survival compared to those without.
Opening excerpt (first ~120 words) tap to expand
A blood test following CAR T-cell therapy for relapsed/refractory mantle cell lymphoma (MCL) appears to do a better job than PET-CT scans at predicting which patients have poor prognoses, a small, retrospective, real-world study finds. In 15 of 18 patients who relapsed, the blood test identified relapse a median of 6.5 months before PET/CT did. “The data from our study supports utilizing this blood test to detect minimal residual disease, and it adds value to PET scans,” said lead author Matthew J. Frank, MD, PhD, in an interview with Medscape Medical News. “We see molecular relapse below the threshold of what a PET-CT scan can show.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
